The Cabinet Member considered a report which indicated that the services covered included Long-Acting Reversible Contraception, NHS Health Checks, Drug Use Shared Care services within primary care, and Pharmacist Supervised Consumption of Prescribed Opiate Substitution Therapy, Needle Exchange Programme and Take-Home Naloxone, within community pharmacy settings
Both DAPL Agreements and associated call-off contracts commenced on 1 April 2022 for a period of four years, were extended for one year under the current contracts, and were due to expire on 31 March 2027.
The current total annual contract value for the Primary Care DAPL was a maximum of £1,354,800 per annum. The proposed total annual contract value for the new Primary Care DAPL contract was approximately £1,540,000 per annum, with a maximum whole-life contract value of approximately £10,780,000.
The current total annual contract value for the Community Healthcare (Pharmacy) DAPL was £270,000 per annum. The proposed total annual contract value for the new Community Healthcare DAPL contract was a maximum of £293,000 per annum, with a maximum whole-life contract value of approximately £2,051,000.
In response to the Cabinet Member and the Shadow Cabinet Member the following was indicated:
· Consultations were private and services were open access.
· Confirmed this would be expected under the Dynamic Approved Provider List. Service users would be provided with sharps bins, and returns could also be made through the Community Drug and Alcohol Treatment Service and some GP practices.
· The medication was available through the community drug and alcohol treatment provider but not through the pharmacy service under consideration.
RESOLVED to:
a) Approve the recommissioning of Long-Acting Reversible Contraception (LARC), NHS Health Checks (NHSHC), and Drug Use Shared Care with eligible providers under the applicable direct award process of the Provider Selection Regime (PSR) as set out in this report.
b) Approve the recommissioning of Pharmacist Supervised Consumption of Prescribed Opiate Substitution Therapy, Needle Exchange Programme and Take-Home Naloxone services with eligible providers under the applicable direct award process of the Provider Selection Regime (PSR), as set out in this report.
c) Delegate authority to the Director of Public Health to award contracts to eligible providers to provide these services for four years, plus three, from 1st April 2027.